Bristol-Myers Squibb (BMY) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Bristol-Myers Squibb Company (BMY) insider buying and selling: no purchases, 4 sales
70 Form 4 Table I transactions filed with the SEC by Bristol-Myers Squibb Company insiders between 2025-09-03 and 2026-10-05 (15-month history): 0 open-market purchases and 4 sales, plus 66 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $2.7M by Elkins David V on 2025-09-02.
Bristol-Myers Squibb insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Bristol-Myers Squibb insiders filed 3 sales worth $2.3M on the open market, and no purchases.
The biggest seller was Elkins David V (EVP, Chief Financial Officer): $1.9M in 1 sale, out of 3 different sellers.
The largest trade of the period was a sale of $1.9M on Apr 1, 2026, by Elkins David V (EVP, Chief Financial Officer). Form 4 on sec.gov (0001451604-26-000004).
None of the 3 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 2 sales, against 0 in the three before. The latest sale from Sep 9, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Bristol-Myers Squibb has more sales than 12 of the other 58, ranks 42 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with BMY's sales, largest first. The full history is in the tool above, already searched.
See all 70 BMY trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-09-02 | 2025-09-03 | Elkins David V | EVP, Chief Financial Officer | $2.7M | S — Open-market sale2 Form 4 footnotesF1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F2 The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.075 to $47.820, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-04-01 | 2026-04-02 | Elkins David V | EVP, Chief Financial Officer | $1.9M | S — Open-market sale3 Form 4 footnotesF1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F2 The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F3 The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-09-09 | 2026-09-10 | Massacesi Cristian | EVP, Chief Med Offr, Head of Dev | $403k | S — Open-market sale | SEC |
| 2026-08-25 | 2026-08-26 | Holzer Phil M | SVP and Controller | $34k | S — Open-market sale | SEC |
| 2026-08-01 | 2026-08-04 | Massacesi Cristian | EVP, Chief Med Offr, Head of Dev | $1.7M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Boerner Christopher S. | Chief Executive Officer | $1.3M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-06-15 | 2026-06-16 | Haller Julia A | Director | $1.1M | M — Option exercise | SEC |
| 2026-03-10 | 2026-03-12 | Elkins David V | EVP, Chief Financial Officer | $969k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Shanahan Karin | EVP, Chief Supply Chain & Ops | $467k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Lenkowsky Adam | EVP, Chief Commercial Officer | $422k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | $396k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Plenge Robert M | EVP, Chief Research Officer | $273k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-06-03 | 2026-06-05 | Short Bartie Wendy | EVP, Corporate Affairs | $212k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of restricted stock units. | SEC |
| 2026-02-01 | 2026-02-03 | Hickey Benjamin | President, RayzeBio Org. | $210k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of restricted stock units. | SEC |
| 2025-11-01 | 2025-11-04 | Shanahan Karin | EVP, Chief Supply Chain & Ops | $148k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-10-02 | 2026-10-05 | Gallman Cari | EVP, General Counsel | $143k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of restricted stock units. | SEC |
| 2026-03-10 | 2026-03-12 | Gallman Cari | EVP, General Counsel | $130k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2025-11-01 | 2025-11-04 | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | $123k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2026-03-10 | 2026-03-12 | Poole Ahn Amanda | EVP, Chief People Officer | $120k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF3 Shares withheld for payment of taxes upon vesting of awards. | SEC |
| 2025-10-02 | 2025-10-06 | Gallman Cari | EVP, General Counsel | $107k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Shares withheld for payment of taxes upon vesting of award. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Sep 3, 2025 and Oct 5, 2026 there is not one open-market purchase of Bristol-Myers Squibb Company: 4 sales worth $4.9M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Bristol-Myers Squibb Company's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 27 | $1.2M |
| F | Tax withholding (shares surrendered for taxes) | 26 | $7.4M |
| J | Other transaction (explained in the filing) | 13 | $0 |
| S | Open-market sale | 4 | $4.9M |
| Total | Everything filed in the period | 70 | $13.5M |
38 of the 70 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 14 distinct people or entities have filed Bristol-Myers Squibb Company transactions: none bought on the open market and 3 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Elkins David V | EVP, Chief Financial Officer | 5 | — | $4.5M (2) | 2026-04-02 |
| Massacesi Cristian | EVP, Chief Med Offr, Head of Dev | 3 | — | $403k (1) | 2026-09-10 |
| Holzer Phil M | SVP and Controller | 4 | — | $34k (1) | 2026-08-26 |
| Gallman Cari | EVP, General Counsel | 9 | — | — | 2026-10-05 |
| Short Bartie Wendy | EVP, Corporate Affairs | 9 | — | — | 2026-09-03 |
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | 7 | — | — | 2026-03-12 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | 7 | — | — | 2026-04-02 |
| Boerner Christopher S. | Chief Executive Officer | 6 | — | — | 2026-03-12 |
Shown here are the 8 who moved the most money, out of 14. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Sep 2025: 0 purchases and 1 sale, worth $2.7M. 11 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $2.7M |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 1 | $1.9M |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 1 | $34k |
| Sep 2026 | 0 | $0 | 1 | $403k |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Bristol-Myers Squibb Company (BMY) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 4 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Bristol-Myers Squibb has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 5, 2026, and a Form 4 arrives up to two business days after the trade.
17 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.